ArticleScientific reports2025
Computational repurposing of drugs against dengue virus targeting NS5 and methyltransferase proteins.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeting Dengue Viral Proteins with Eco-Friendly Nanotechnology: A Promising Path for Antiviral Research.Viruses · 2026Review
- Benzilmonoximethiocarbohydrazide Schiff bases as multifunctional antimalarial and antioxidant scaffolds: synthesis, biological evaluation, and mechanistic insights.RSC advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Dengue virus (DENV) remains a significant global health challenge, infecting approximately 400 million individuals annually. This study utilizes molecular docking and molecular dynamics (MD) simulations to investigate the binding dynamics and stability of Avermectin and Doramectin with DENV Methyltransferase (MTase) and NS5 proteins. Root Mean Squared Deviation (RMSD) analysis revealed stable complexes, with values ranging from 2.5 to 3.2 Å. The radius of gyration (Rg) values stabilized around 20-23 Å, indicating compact structural integrity. Binding free energy calculations demonstrated that Doramectin exhibited stronger predicted binding and may offer improved inhibitory potential, with ΔG values of -13.9 ± 2.8 kcal/mol for MTase and - 23.8 ± 0.82 kcal/mol for NS5, compared to Avermectin (-5.8 ± 1.2 kcal/mol and - 4.8 ± 0.52 kcal/mol, respectively). Dynamic Cross-Correlation Matrix (DCCM) analysis identified critical correlated motions in key binding residues, such as Gly79 and Arg78 in MTase and Gly104 and Arg155 in NS5, emphasizing Doramectin's role in stabilizing protein conformations. Key interactions through hydrogen bonding and residue mapping, involving Ser50, Gly52, and Asp141, played pivotal roles in inhibitor binding. This study highlights Doramectin as a promising candidate for further investigation in the treatment of Dengue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.